| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/24/2013 | US8541374 Use of a composition comprising a non-fermented rice peptidic hydrolyzate for stimulating hair growth |
| 09/24/2013 | US8541372 Isolated extracellular matrix material including subserous fascia |
| 09/24/2013 | US8541371 Treatment of conditions related to cecal ligation shock |
| 09/24/2013 | US8541370 Use of matrix metalloproteinase-10 (MMP-10) for thrombolytic treatments |
| 09/24/2013 | US8541369 Fibroblast growth factor 21 variants having improved pharmacological potency and/or improved pharmaceutical stability |
| 09/24/2013 | US8541368 Glucagon analogues |
| 09/24/2013 | US8541367 Plasma anti-diabetic NUCB2 peptide (pladin) and uses thereof |
| 09/24/2013 | US8541365 Dendrimeric compounds comprising amino acids, hyperbranched core compound, process for preparation of dendrimeric compounds comprising amino acids and hyperbranched core compound, and use thereof |
| 09/24/2013 | US8541364 Use of a octreotide as a therapeutic agent |
| 09/24/2013 | US8541361 Composition |
| 09/24/2013 | US8541360 Parenteral formulations comprising sugar-based esters and ethers |
| 09/24/2013 | US8541359 Pharmaceutical compositions and methods for peptide treatment |
| 09/24/2013 | US8541236 Oxidation resistant mutant apoA-I polypeptide having a combination of: a conservative amino acid substitution at residue Tyr192; and at least one conservative amino acid substitution at residue Met86, Met112, or Met148; promoting cholesterol efflux; atherosclerosis |
| 09/24/2013 | US8541230 Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
| 09/24/2013 | US8541023 Immunogenic compositions containing phospholipid |
| 09/24/2013 | US8541008 Monoclonal antibody against an ALS1 protein that specifically binds an epitope in an N-terminal domain and which inhibits adherence of Candida albicans to endothelial cells. |
| 09/24/2013 | US8541002 Vaccine for treatment and prevention of herpes simplex virus infection |
| 09/24/2013 | US8540999 Allergenic proteins and peptides from Japanese cedar pollen |
| 09/24/2013 | US8540997 Complement receptor 1 and 2 fusion proteins |
| 09/24/2013 | US8540983 Debriding composition from bromelain and methods of production thereof |
| 09/24/2013 | US8540977 IL-11 muteins |
| 09/24/2013 | US8540964 Polyvalent conjugate vaccine for cancer |
| 09/24/2013 | CA2770851C Blockade of t lymphocyte down-regulation associated with ctla-4 signaling |
| 09/24/2013 | CA2691691C Compositions and methods of treating chronic kidney disease |
| 09/24/2013 | CA2680378C Method for determining physiological effects of hemoglobin |
| 09/24/2013 | CA2578176C Ophthalmic emulsions containing an immunosuppressive agent |
| 09/24/2013 | CA2557645C Caspase inhibitors and uses thereof |
| 09/24/2013 | CA2539567C Nutritional and therapeutic compositions to increase bodily glutathione levels |
| 09/24/2013 | CA2538408C Diet product, oral drug and method for treating allergies using tgf-.beta.1 |
| 09/24/2013 | CA2515453C Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| 09/24/2013 | CA2486583C Marker molecules associated with lung tumors |
| 09/24/2013 | CA2480656C Bioadhesive directed somatic cell therapy |
| 09/24/2013 | CA2476410C Methods to increase or decrease bone density |
| 09/24/2013 | CA2466697C Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission |
| 09/24/2013 | CA2448427C Molecules and methods for inhibiting shedding of kim-1 |
| 09/24/2013 | CA2434760C Differentiated cells suitable for human therapy |
| 09/24/2013 | CA2425669C Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis |
| 09/24/2013 | CA2405557C Albumin fusion proteins |
| 09/24/2013 | CA2318857C Use of heregulin as an epithelial cell growth factor |
| 09/24/2013 | CA2312478C G-protein coupled receptors and uses therefor |
| 09/19/2013 | WO2013138811A1 Niche-specific treatment infrastructure continuum |
| 09/19/2013 | WO2013138790A1 Combination therapies including inhibitors of the extracellular domain of e-cadherin |
| 09/19/2013 | WO2013138731A1 Polymeric conjugates of c1-inhibitors |
| 09/19/2013 | WO2013138704A1 Protein to promote blood vessel growth and uses thereof |
| 09/19/2013 | WO2013138694A1 Polymeric conjugates of c-1 inhibitors |
| 09/19/2013 | WO2013138484A1 Method to prevent cancer metastasis and inhibit inflammation by inhibition of p68 interaction with calmodulin |
| 09/19/2013 | WO2013138352A1 Formulations of guanylate cyclase c agonists and methods of use |
| 09/19/2013 | WO2013138340A1 Melanocortin analogs having enhanced activity and transport |
| 09/19/2013 | WO2013138338A2 Methods for treating tissue damage associated with ischemia with apoliporotein d |
| 09/19/2013 | WO2013138271A1 The use of antithrombin in the treatment of pre-eclampsia |
| 09/19/2013 | WO2013138259A2 Polypeptides for treating and/or limiting influenza infection |
| 09/19/2013 | WO2013138238A1 Methods and compositions for treating wounds and reducing the risk of incisional hernias |
| 09/19/2013 | WO2013138118A1 Treatment of inflammatory disorders in non-human mammals |
| 09/19/2013 | WO2013138064A1 Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
| 09/19/2013 | WO2013137920A1 Engineered conformationally-stabilized proteins |
| 09/19/2013 | WO2013137869A1 Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
| 09/19/2013 | WO2013137782A1 Agent for the treatment of hepatitis c virus |
| 09/19/2013 | WO2013137777A1 Pharmaceutical composition having neuroprotector, antiamnesic, antioxidant, antihypoxic, neurometabolic and antiischaemic activity (alternatives) |
| 09/19/2013 | WO2013137606A1 Pharmaceutical composition for preventing or treating arteriosclerosis |
| 09/19/2013 | WO2013137569A1 Tetrapeptide, and skin antiaging and anti-inflammatory cosmetic composition containing same |
| 09/19/2013 | WO2013137396A1 NOVEL INTEGRIN α9β1 LIGAND AND USES THEREOF |
| 09/19/2013 | WO2013137197A1 Biofilm inhibitor |
| 09/19/2013 | WO2013136871A1 Oversulfated chondroitin composition |
| 09/19/2013 | WO2013136338A1 Modified kisspeptin peptides and uses thereof |
| 09/19/2013 | WO2013136277A1 Pharmaceutical compositions for treatment of cardiovascular diseases |
| 09/19/2013 | WO2013136234A1 Transdermal delivery devices |
| 09/19/2013 | WO2013136175A2 New repeat variable diresidues for targeting nucleotides |
| 09/19/2013 | WO2013136086A1 A negative modulator of hedgehog signalling for use in treating th2 -mediated diseases |
| 09/19/2013 | WO2013136078A1 Therapeutic use of p75ntr neurotrophin binding protein |
| 09/19/2013 | WO2013136040A1 Polypeptides and their use |
| 09/19/2013 | WO2013135928A1 Use of obestatin for muscle regeneration |
| 09/19/2013 | WO2013135880A1 Combination of a mc1r receptor agonist and uvb for the treatment and/or prevention of pigmentation disorders |
| 09/19/2013 | WO2013135266A1 Treatment of non-small cell lung carcinoma by active immunotherapy |
| 09/19/2013 | WO2013134822A1 Method for treating inflammation |
| 09/19/2013 | WO2013113030A3 Fads regulation |
| 09/19/2013 | WO2013100821A3 Agent for treating diabetes |
| 09/19/2013 | US20130247233 G protein coupled receptors and uses thereof |
| 09/19/2013 | US20130245601 Intradermal delivery of substances |
| 09/19/2013 | US20130245097 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| 09/19/2013 | US20130245090 Identification of novel genes coding for small temporal rnas |
| 09/19/2013 | US20130245037 Stabilization of Hypoxia Inducible Factor (HIF) Alpha |
| 09/19/2013 | US20130244957 Methods for preventing or treating mitochondrial permeability transition |
| 09/19/2013 | US20130244954 Use of reg4 and pharmaceutical composition thereof |
| 09/19/2013 | US20130244950 Combination therapy for chemoresistant cancers |
| 09/19/2013 | US20130244948 Compositions of cells, media, and methods thereof |
| 09/19/2013 | US20130244941 Use Of C1 Inhibitor For The Prevention Of Ischemia-Reperfusion Injury |
| 09/19/2013 | US20130244939 Novel peptides that bind to the erythropoietin receptor |
| 09/19/2013 | US20130244937 Chimeric natriuretic peptide compositions and methods of preparation |
| 09/19/2013 | US20130244935 Methods of Treating Necrotizing Enterocolitis Using Heparin Binding Epidermal Growth Factor |
| 09/19/2013 | US20130244934 Vip fragments and methods of use |
| 09/19/2013 | US20130244932 E-prostanoid receptor, ptger3, as a novel anti-diabetic therapeutic target |
| 09/19/2013 | US20130244931 Novel GLP-1 Derivatives |
| 09/19/2013 | US20130244929 Bridged lipoglycopeptides that potentiate the activity of beta-lactam antibacterials |
| 09/19/2013 | US20130244928 Antimicrobial peptides and derived metapeptides |
| 09/19/2013 | US20130244927 Polynucleotides encoding signal peptide-containing molecules |
| 09/19/2013 | US20130244926 Medicament for therapeutic treatment and/or improvement of sepsis |
| 09/19/2013 | US20130244925 Molecules mimicking an autoantibody idiotype and compositions containing same |
| 09/19/2013 | US20130244924 Peptide compounds to regulate the complement system |
| 09/19/2013 | US20130243886 Novel use |
| 09/19/2013 | US20130243873 Immunomodulatory compositions |